$XNCR

Feigal Ellen sold $89K of XNCR

Feigal Ellen sold 6,843 shares of Xencor Inc (XNCR) at $13.06 on 2026-06-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Feigal Ellen
Published Jun 22, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$XNCR
Neutral
medium confidence
Mentioned
$XNCR
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XNCRNeutralLow
01

Why it matters

The disclosed sale is a new, primary-source datapoint but is likely low-impact because it is pre-arranged under Rule 10b5-1 and lacks accompanying company-specific news.

02

Market read

Traders may briefly reassess sentiment around insider activity, but the 10b5-1 structure reduces the likelihood of a durable fundamental repricing.

03

What to watch

The filing does not state whether additional sales are planned, nor does it provide context on total insider holdings beyond the post-transaction figure; without that, signal quality is limited.

Relevance 2/10Novelty 4/10Timing: after-hours/filing time (2026-06-22) for an insider sale disclosed on SEC EDGAR

Background

The article is an SEC Form 4 insider transaction disclosure for Xencor Inc, reported by director Feigal Ellen.

Company-level read

Ticker impact

$XNCRNeutralMedium confidence
Context

SEC Form 4 shows director Feigal Ellen sold 6,843 shares of Xencor at $13.0600 on 2026-06-18 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed insider transaction with a pre-arranged 10b5-1 plan, and the article contains no new operational, financial, or regulatory developments.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations; traders may ignore it unless paired with other negative catalysts.

Key entities

  • Xencor Inc

    Subject of the Form 4 insider transaction; director Feigal Ellen sold shares under a 10b5-1 plan.

  • Feigal Ellen

    Director who sold 6,843 shares at $13.0600 on 2026-06-18; holdings after sale: 12,340 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$XNCRHighAI 8/10

Truist raises Xencor stock price target on kidney cancer drug data

Truist Securities raised its price target for Xencor (XNCR) to $40 from $29, citing positive clinical data for XmAb819 in kidney cancer. The stock has gained 17% in a week. Truist increased peak sales estimates to $1.1B and success probability to 35%. XNCR's market cap is $2.18B, with a 91% YTD return. Other analysts also upgraded price targets based on ESMO conference data.